Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 162

1.

Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.

Vesikari T, Rivera L, Korhonen T, Ahonen A, Cheuvart B, Hezareh M, Janssens W, Mesaros N.

Hum Vaccin Immunother. 2017 Mar 24:1-11. doi: 10.1080/21645515.2017.1294294. [Epub ahead of print]

PMID:
28340322
2.

Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials.

Norrby M, Vesikari T, Lindqvist L, Maeurer M, Ahmed R, Mahdavifar S, Bennett S, McClain JB, Shepherd BM, Li D, Hokey DA, Kromann I, Hoff ST, Andersen P, de Visser AW, Joosten SA, Ottenhoff TH, Andersson J, Brighenti S.

Vaccine. 2017 Mar 14;35(12):1652-1661. doi: 10.1016/j.vaccine.2017.01.055. Epub 2017 Feb 17.

3.

Rotavirus epidemiology 5-6 years after universal rotavirus vaccination: persistent rotavirus activity in older children and elderly.

Markkula J, Hemming-Harlo M, Salminen MT, Savolainen-Kopra C, Pirhonen J, Al-Hello H, Vesikari T.

Infect Dis (Lond). 2017 May;49(5):388-395. doi: 10.1080/23744235.2016.1275773. Epub 2017 Jan 9.

PMID:
28067093
4.

Epidemiology of two human protoparvoviruses, bufavirus and tusavirus.

Väisänen E, Paloniemi M, Kuisma I, Lithovius V, Kumar A, Franssila R, Ahmed K, Delwart E, Vesikari T, Hedman K, Söderlund-Venermo M.

Sci Rep. 2016 Dec 14;6:39267. doi: 10.1038/srep39267.

5.

Concomitant administration of a fully liquid, ready-to-use DTaP-IPV-HB-PRP-T hexavalent vaccine with a meningococcal serogroup C conjugate vaccine in infants.

Vesikari T, Borrow R, Da Costa X, Richard P, Eymin C, Boisnard F, Lockhart S.

Vaccine. 2017 Jan 11;35(3):452-458. doi: 10.1016/j.vaccine.2016.11.053. Epub 2016 Dec 9.

PMID:
27939054
6.

A Phase III Randomized, Double-blind, Clinical Trial of an Investigational Hexavalent Vaccine Given at Two, Three, Four and Twelve Months.

Vesikari T, Becker T, Vertruyen AF, Poschet K, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.

Pediatr Infect Dis J. 2017 Feb;36(2):209-215. doi: 10.1097/INF.0000000000001406.

PMID:
27846055
7.

Sustained High Effectiveness of RotaTeq on Hospitalizations Attributable to Rotavirus-Associated Gastroenteritis During 4 Years in Finland.

Hemming-Harlo M, Vesikari T, Uhari M, Renko M, Salminen M, Torcel-Pagnon L, Hartwig S, Simondon F, Bricout H.

J Pediatric Infect Dis Soc. 2016 Oct 19. pii: piw061. [Epub ahead of print]

PMID:
27760800
8.

A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule.

Vesikari T, Silfverdal SA, Jordanov E, Feroldi E.

Pediatr Infect Dis J. 2017 Jan;36(1):87-93.

PMID:
27753797
9.

Norovirus-Specific Memory T Cell Responses in Adult Human Donors.

Malm M, Tamminen K, Vesikari T, Blazevic V.

Front Microbiol. 2016 Oct 3;7:1570. eCollection 2016 Oct 3.

10.

Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles.

Malm M, Tamminen K, Lappalainen S, Vesikari T, Blazevic V.

J Immunol Res. 2016;2016:9171632. Epub 2016 Sep 4.

11.

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group..

N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.

12.

Type-specific and cross-reactive antibodies and T cell responses in norovirus VLP immunized mice are targeted both to conserved and variable domains of capsid VP1 protein.

Malm M, Tamminen K, Vesikari T, Blazevic V.

Mol Immunol. 2016 Oct;78:27-37. doi: 10.1016/j.molimm.2016.08.009. Epub 2016 Aug 29.

PMID:
27573255
13.

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study.

Pepin S, Szymanski H, Rochín Kobashi IA, Villagomez Martinez S, González Zamora JF, Brzostek J, Huang LM, Chiu CH, Chen PY, Ahonen A, Forstén A, Seppä I, Quiroz RF, Korhonen T, Rivas E, Monfredo C, Hutagalung Y, Menezes J, Vesikari T.

Hum Vaccin Immunother. 2016 Dec;12(12):3072-3078. doi: 10.1080/21645515.2016.1212143. Epub 2016 Aug 26.

14.

Simple and efficient ultrafiltration method for purification of rotavirus VP6 oligomeric proteins.

Lappalainen S, Vesikari T, Blazevic V.

Arch Virol. 2016 Nov;161(11):3219-23. doi: 10.1007/s00705-016-2991-8. Epub 2016 Aug 12.

PMID:
27518400
15.

Decrease of Rotavirus Gastroenteritis to a Low Level Without Resurgence for Five Years After Universal RotaTeq Vaccination in Finland.

Hemming-Harlo M, Markkula J, Huhti L, Salminen M, Vesikari T.

Pediatr Infect Dis J. 2016 Dec;35(12):1304-1308.

PMID:
27455440
16.

Rotavirus vaccination and infection induce VP6-specific IgA responses.

Lappalainen S, Blazevic V, Malm M, Vesikari T.

J Med Virol. 2017 Feb;89(2):239-245. doi: 10.1002/jmv.24636. Epub 2016 Aug 6.

PMID:
27431308
17.

A Phase III randomized, double-blind, clinical trial of an investigational hexavalent vaccine given at 2, 4, and 11-12 months.

Silfverdal SA, Icardi G, Vesikari T, Flores SA, Pagnoni MF, Xu J, Liu GF, Stek JE, Boisnard F, Thomas S, Ziani E, Lee AW.

Vaccine. 2016 Jul 19;34(33):3810-6. doi: 10.1016/j.vaccine.2016.05.054. Epub 2016 Jun 18.

PMID:
27288217
18.

Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination.

Steele AD, Madhi SA, Cunliffe NA, Vesikari T, Phua KB, Lim FS, Nelson EA, Lau YL, Huang LM, Karkada N, Debrus S, Han HH, Benninghoff B.

Hum Vaccin Immunother. 2016 Sep;12(9):2406-12. doi: 10.1080/21645515.2016.1179412. Epub 2016 Jun 3.

19.

Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding.

Tamminen K, Malm M, Vesikari T, Blazevic V.

Viral Immunol. 2016 Jun;29(5):315-9. doi: 10.1089/vim.2015.0141. Epub 2016 May 2.

PMID:
27135874
20.

Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid).

Esposito S, Bonanni P, Maggi S, Tan L, Ansaldi F, Lopalco PL, Dagan R, Michel JP, van Damme P, Gaillat J, Prymula R, Vesikari T, Mussini C, Frank U, Osterhaus A, Celentano LP, Rossi M, Guercio V, Gavazzi G.

Hum Vaccin Immunother. 2016 Jul 2;12(7):1777-94. doi: 10.1080/21645515.2016.1150396. Epub 2016 May 2.

PMID:
27135390

Supplemental Content

Loading ...
Support Center